| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
Mangafodipir's active metabolite, fodipir, plays a role in mangafodipir-mediated cytoprotection against cell death caused by 7β-hydroxycholesterol. After 8 hours of therapy, fodipir (Dp-dp; dipyridine diphosphate; 100 μM) demonstrated optimum cytoprotective benefits against 7β-OH-mediated cell death. Additionally, fodipir decreases lysosomal membrane permeabilization (LMP) and ROS generation in cells caused by 7β-OH [1].
|
|---|---|
| References |
| Molecular Formula |
C22H32N4O14P2
|
|---|---|
| Molecular Weight |
638.45548
|
| Exact Mass |
638.139
|
| CAS # |
118248-91-2
|
| PubChem CID |
60683
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.657g/cm3
|
| Boiling Point |
1049.1ºC at 760mmHg
|
| Flash Point |
588.3ºC
|
| Vapour Pressure |
0mmHg at 25°C
|
| Index of Refraction |
1.655
|
| LogP |
0.132
|
| Hydrogen Bond Donor Count |
8
|
| Hydrogen Bond Acceptor Count |
18
|
| Rotatable Bond Count |
17
|
| Heavy Atom Count |
42
|
| Complexity |
907
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
SQKUFYLUXROIFM-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H32N4O14P2/c1-13-21(31)17(15(5-23-13)11-39-41(33,34)35)7-25(9-19(27)28)3-4-26(10-20(29)30)8-18-16(12-40-42(36,37)38)6-24-14(2)22(18)32/h5-6,31-32H,3-4,7-12H2,1-2H3,(H,27,28)(H,29,30)(H2,33,34,35)(H2,36,37,38)
|
| Chemical Name |
2-[2-[carboxymethyl-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methyl]amino]ethyl-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methyl]amino]acetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~18.18 mg/mL (~28.47 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 33.33 mg/mL (52.20 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5663 mL | 7.8313 mL | 15.6627 mL | |
| 5 mM | 0.3133 mL | 1.5663 mL | 3.1325 mL | |
| 10 mM | 0.1566 mL | 0.7831 mL | 1.5663 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
